NCT01053884 - Anidulafungin in Patients With Hematologic Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions

Hematologic Malignancies

Interventions

DRUG

Anidulafungin

"standard dose: 200mg/d on day 1, followed by 100mg/d from day 2 as maintenance dose.~Prophylaxis will be given until the recovery from neutropenia (ANC \> 1,0 G/L without myelosupportive medications) and in cases of active fungal infection until best response, in case of fungemia for at least 2 weeks after the first negative culture."

Trial Locations (1)

4020

Elisabethinen hospital, Linz